Christopher Peetz - 09 Jan 2023 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Issuer symbol
MIRM
Transactions as of
09 Jan 2023
Net transactions value
-$106,390
Form type
4
Filing time
18 Mar 2024, 17:37:30 UTC
Previous filing
05 Jan 2023
Next filing
02 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Sale $106,390 -5,159 -5.3% $20.62 91,953 09 Jan 2023 Direct F1, F2
holding MIRM Common Stock 208,570 09 Jan 2023 By The Peetz Family Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units.
F2 7,000 shares held indirectly by the reporting person were inadvertently reported on prior Form 4 filings as direct holdings. The reporting person's holdings on this Form 4 have been adjusted accordingly.